What is on the table
The foundation is assessing whether to back research in China as it sees Chinese scientists pushing further into innovation. "China has changed radically," CEO Mads Krogsgaard Thomsen said in a Friday interview in London, pointing to the country's drive to create more innovative medicines. He also noted he was involved when Novo Nordisk became the first global drugmaker to open a China research center in 1997.
Thomsen said he is discussing the idea with the board and is targeting a China strategy within a year.
Guardrails and what is out
Thomsen framed potential collaboration around pre-competitive work that benefits everyone. As he put it, "If you can find areas where pre-competitive things like climate solutions, sustainable agriculture, where you actually can benefit the globe by working together also with China, that might be a win-win situation for the earth." He added the foundation would structure any grants to have wide benefits and avoid skewing competition.
He said this approach would likely rule out its quantum computing portfolio from any China plan.
When big funding decisions are debated, staying informed helps you see broader implications, so sign up for Market Briefs today
Where else the money is going
The foundation has been increasing its international grant share, with around 21% of funding outside Denmark last year, up from 13%. Novo Holdings manages roughly $102 billion for the foundation and holds controlling stakes in other life science businesses as well as Novo Nordisk. The foundation also has regional efforts in Southeast Asia and India.
On health research, Thomsen said there is still room for new ideas in obesity even as drugmakers pursue next generation cardiometabolic drugs. "It's a crowded area, but it's crowded with very few targets," he said, noting that most competitors center on GLP-1, GIP, amylin and glucagon peptides. He said the foundation can help by funding scientists looking for entirely new targets for these diseases.
Separately, the foundation is ramping up quantum computing support. Thomsen said Europe fell behind in building new hardware for artificial intelligence but could still lead in quantum if it avoids overregulating the young sector. Read More: Novo Owner to Build $62 Million Quantum Chip Plant in Denmark
Investor take
For investors tracking Novo Nordisk and its owner ecosystem, three signals stand out: potential pre-competitive China projects, a rising share of cross-border grants, and a push into quantum alongside continued interest in new obesity targets. None of this changes the near term for your portfolio on its own, but it does sketch where future research partnerships and noncompetitive science money could flow.
Across sectors and borders it's useful to get clear context each morning, so get the free Market Briefs newsletter
